Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide.

Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.
Journal of Neuroscience Research (Impact Factor: 2.97). 09/2003; 73(4):481-96. DOI: 10.1002/jnr.10681
Source: PubMed

ABSTRACT 6-aminonicotinamide (6-AN) is a niacin antagonist, which leads to degeneration of gray matter astrocytes mainly in the brainstem. We have examined the role of interleukin-6 (IL-6) in this degenerative process by using transgenic mice with astrocyte-targeted IL-6 expression (GFAP-IL6 mice). This study demonstrates that transgenic IL-6 expression significantly increases the 6-AN-induced inflammatory response of reactive astrocytes, microglia/macrophages, and lymphocytes in the brainstem. Also, IL-6 induced significant increases in proinflammatory cytokines IL-1, IL-12, and tumor necrosis factor-alpha as well as growth factors basic fibroblast growth factor (bFGF), transforming growth factor-beta, neurotrophin-3, angiopoietin, vascular endothelial growth factor, and the receptor for bFGF. In accordance, angiogenesis was increased in GFAP-IL6 mice relative to controls after 6-AN. Moreover, oxidative stress and apoptotic cell death were significantly reduced by transgenic IL-6 expression. IL-6 is also a major inducer in the CNS of metallothionein I and II (MT-I+II), which were significantly increased in the GFAP-IL6 mice. MT-I+II are antioxidants and neuroregenerative factors in the CNS, so increased MT-I+II levels in GFAP-IL6 mice could contribute to the reduction of oxidative stress and cell death in these mice.

  • Source
    Brain Injury - Pathogenesis, Monitoring, Recovery and Management, 12/2011; , ISBN: 978-953-51-0265-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Almost a quarter of a century ago, interleukin-6 (IL-6) was discovered as an inflammatory cytokine involved in B cell differentiation. Today, IL-6 is recognized to be a highly versatile cytokine, with pleiotropic actions not only in immune cells, but also in other cell types, such as cells of the central nervous system (CNS). The first evidence implicating IL-6 in brain-related processes originated from its dysregulated expression in several neurological disorders such as multiple sclerosis, Alzheimer's disease and Parkinson's disease. In addition, IL-6 was shown to be involved in multiple physiological CNS processes such as neuron homeostasis, astrogliogenesis and neuronal differentiation. The molecular mechanisms underlying IL-6 functions in the brain have only recently started to emerge. In this review, an overview of the latest discoveries concerning the actions of IL-6 in the nervous system is provided. The central position of IL-6 in the neuroinflammatory reaction pattern, and more specifically, the role of IL-6 in specific neurodegenerative processes, which accompany Alzheimer's disease, multiple sclerosis and excitotoxicity, are discussed. It is evident that IL-6 has a dichotomic action in the CNS, displaying neurotrophic properties on the one hand, and detrimental actions on the other. This is in agreement with its central role in neuroinflammation, which evolved as a beneficial process, aimed at maintaining tissue homeostasis, but which can become malignant when exaggerated. In this perspective, it is not surprising that 'well-meant' actions of IL-6 are often causing harm instead of leading to recovery.
    Brain Research Reviews 01/2011; 67(1-2):157-83. · 7.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Das Schdel-Hirn-Trauma (SHT) wurde in den letzten Jahren als ein vorwiegend immunologisches und entzndliches Krankheitsbild neu definiert. Diese Erkenntnis basiert auf der Einsicht, dass die berschieende Entzndungsreaktion im verletzten Gehirn zur Ausbildung des posttraumatischen Hirndems fhrt und sich dadurch mageblich limitierend auf die Prognose der SHT-Patienten auswirkt. Whrend die Vermittler der Neuroinflammation (z.B. die Zytokin-Kaskade oder das Komplementsystem) durch Studien am Tiermodell weitgehend charakterisiert sind, bleiben deren Interaktionen und pathophysiologische Implikationen im verletzten Gehirn noch unzureichend geklrt. Das mangelnde Verstndnis beruht u.a. auf der dualen Funktion der neuroinflammatorischen Reaktion nach SHT. Diese zweischneidige Rolle impliziert, dass spezifische Entzndungsmediatoren je nach lokaler Konzentration, Zeitpunkt und Ort ihrer Expression im Gehirn unterschiedliche Funktionen vermitteln knnen, von einer gewnschten Neuroprotektion bis hin zur detrimentalen Neurotoxizitt.Der ausbleibende Erfolg antiinflammatorischer Therapieanstze bei SHT-Patienten verdeutlicht die dringende Notwendigkeit der Intensivierung der Grundlagenforschung auf dem Gebiet der posttraumatischen intrazerebralen Entzndungsreaktion. Die vorliegende Arbeit soll die aktuellsten Ergebnisse der experimentellen Forschung auf diesem speziellen Gebiet zusammenfassen und potentielle zuknftige Forschungsrichtungen errtern.Research efforts in recent years have defined traumatic brain injury (TBI) as a predominantly immunological and inflammatory disorder. This perception is based on the fact that the overwhelming neuroinflammatory response in the injured brain contributes to the development of posttraumatic edema and to neuropathological sequelae which are, in large part, responsible for the adverse outcome. While the key mediators of neuroinflammation, such as the cytokine cascade and the complement system, have been clearly defined by studies in experimental TBI models, their exact pathways of interaction and pathophysiological implications remain to be further elucidated. This lack of knowledge is partially due to the concept of a dual role of the neuroinflammatory response after TBI. This notion implies that specific inflammatory molecules may mediate diverse functions depending on their local concentration and kinetics of expression in the injured brain. The inflammation-induced effects range from beneficial aspects of neuroprotection to detrimental neurotoxicity.The lack of success in pushing anti-inflammatory therapeutic concepts frombench to bedside for patients with severe TBI strengthens the further need for advances in basic research on the molecular aspects of the neuroinflammatory network in the injured brain. The present review summarizes the current knowledge from experimental studies in this field of research and discusses potential future targets of investigation.
    Der Orthopäde 01/2007; 36(3):248-258. · 0.51 Impact Factor